Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Bone metastases occur in approximately 70% of metastatic breast cancer patients, often leading to skeletal injuries. Current treatments are mainly palliative and underscore the unmet clinical need for improved therapies. In this study, we provide preclinical evidence for an antimetastatic therapy based on targeting integrin β3 (β3), which is selectively induced on breast cancer cells in bone by the local bone microenvironment. In a preclinical model of breast cancer, β3 was strongly expressed on bone metastatic cancer cells, but not primary mammary tumors or visceral metastases. In tumor tissue from breast cancer patients, β3 was significantly elevated on bone metastases relative to primary tumors from the same patient (n = 42). Mechanistic investigations revealed that TGFβ signaling through SMAD2/SMAD3 was necessary for breast cancer induction of β3 within the bone. Using a micelle-based nanoparticle therapy that recognizes integrin αvβ3 (αvβ3-MPs of ∼12.5 nm), we demonstrated specific localization to breast cancer bone metastases in mice. Using this system for targeted delivery of the chemotherapeutic docetaxel, we showed that bone tumor burden could be reduced significantly with less bone destruction and less hepatotoxicity compared with equimolar doses of free docetaxel. Furthermore, mice treated with αvβ3-MP-docetaxel exhibited a significant decrease in bone-residing tumor cell proliferation compared with free docetaxel. Taken together, our results offer preclinical proof of concept for a method to enhance delivery of chemotherapeutics to breast cancer cells within the bone by exploiting their selective expression of integrin αvβ3 at that metastatic site. Cancer Res; 77(22); 6299–312. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · cited 4×
“In addition, TGFβR1 can activate ‘non-canonical’ signaling pathways, most commonly p38 MAP kinase (p38), MAPK/ERK Kinase-1&-2 (MEK1/2), and c-Jun N-terminal kinase (JNK) (39).”
InfluentialSteeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Cited by
Understanding the Bone in Cancer Metastasis
Fornetti, J., Welm, A. L., & Stewart, S. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3618 · Cited by 526
Molecular mechanosensors in osteocytes
Qin, L., Liu, W., Cao, H., & Xiao, G. (2020) · Bone Research · doi:10.1038/s41413-020-0099-y · Cited by 484
Metastasis Organotropism: Redefining the Congenial Soil
Gao, Y., Bado, I., Wang, H., Zhang, W., Rosen, J. M., & Zhang, X. H.-F. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.012 · Cited by 380
Murali, B., Ren, Q., Luo, X., Faget, D. V., Wang, C., Johnson, R. M., Gruosso, T., Flanagan, K. C., Fu, Y., Leahy, K., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0234 · Cited by 67
“TMA Staining and Analysis As previously described (32), patient-derived samples from primary breast cancer were collected from patients without detectable bone metastases at diagnosis, and matching bone metastases were collected at a later date (at least 6 months after initial diagnosis).”
Self-citationCrippa, M., Bersini, S., Gilardi, M., Arrigoni, C., Gamba, S., Falanga, A., Candrian, C., Dubini, G., Vanoni, M., & Moretti, M. (2021) · Lab on a Chip · doi:10.1039/d0lc01011a · Cited by 37
Metadata
- Authors
- Ross, M. H., Esser, A. K., Fox, G. C., Schmieder, A. H., Yang, X., Hu, G., Pan, D., Su, X., Xu, Y., Novack, D. V., Walsh, T., Colditz, G. A., Lukaszewicz, G. H., Cordell, E., Novack, J., Fitzpatrick, J. A. J., Waning, D. L., Mohammad, K. S., Guise, T. A., Lanza, G. M., & Weilbaecher, K. N.
- Venue
- Cancer Research
- Published
- 2017-11-14
- Volume
- 77
- Issue
- 22
- Pages
- 6299-6312
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2750781621
- Cited by
- 90
- References
- 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases. https://app.cochat.ai/papers/10.1158/0008-5472.can-17-1225
- The paper
- Ross, M. H., Esser, A. K., Fox, G. C., Schmieder, A. H., Yang, X., Hu, G., Pan, D., Su, X., Xu, Y., Novack, D. V., Walsh, T., Colditz, G. A., Lukaszewicz, G. H., Cordell, E., Novack, J., Fitzpatrick, J. A. J., Waning, D. L., Mohammad, K. S., Guise, T. A., . . . Weilbaecher, K. N. (2017). Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases. Cancer Research. https://doi.org/10.1158/0008-5472.can-17-1225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.